These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 39003670)

  • 1. Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USA.
    Van de Wiele VL; Kesselheim AS; Gleeson D; Lu Z; Tu SS; Rome BN
    Pharmaceut Med; 2024 Jul; 38(4):303-310. PubMed ID: 39003670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018.
    Rome BN; Lee CC; Kesselheim AS
    Clin Pharmacol Ther; 2021 Feb; 109(2):367-371. PubMed ID: 32654122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
    Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
    BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study.
    Lexchin J
    Value Health; 2017 Sep; 20(8):1139-1142. PubMed ID: 28964446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of Market Exclusivity for Prescription Drugs in the United States.
    Kesselheim AS; Sinha MS; Avorn J
    JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Method for Approximating Future Entry of Generic Drugs.
    Beall RF; Darrow JJ; Kesselheim AS
    Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variations in time of market exclusivity among top-selling prescription drugs in the United States.
    Wang B; Liu J; Kesselheim AS
    JAMA Intern Med; 2015 Apr; 175(4):635-7. PubMed ID: 25664700
    [No Abstract]   [Full Text] [Related]  

  • 9. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Onset of Biosimilar Versus Generic Competition in the United States.
    Beall RF; Ronksley PE; Wick J; Darrow JJ; Sarpatwari A; Kesselheim AS
    Clin Pharmacol Ther; 2020 Dec; 108(6):1308-1314. PubMed ID: 32621540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated trends in US brand-name and generic drug competition.
    Grabowski H; Long G; Mortimer R; Boyo A
    J Med Econ; 2016 Sep; 19(9):836-44. PubMed ID: 27064194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Market exclusivity for top-selling pharmaceuticals: too long, too short, or just right?
    Downing NS
    JAMA Intern Med; 2015 Apr; 175(4):637-8. PubMed ID: 25664529
    [No Abstract]   [Full Text] [Related]  

  • 13. Market Exclusivity and Changes in Competition and Prices Associated With the US Food and Drug Administration Unapproved Drug Initiative.
    Gunter SJ; Kesselheim AS; Rome BN
    JAMA Intern Med; 2021 Aug; 181(8):1124-1126. PubMed ID: 33999110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
    Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
    JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.
    Horrow C; Gabriele SME; Tu SS; Sarpatwari A; Kesselheim AS
    JAMA Intern Med; 2024 Jul; 184(7):810-817. PubMed ID: 38739386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
    Kerr KW; Glos LJ
    Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure.
    Magazzini L; Pammolli F; Riccaboni M
    Eur J Health Econ; 2004 Jun; 5(2):175-82. PubMed ID: 15452754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modifying the Criteria for Granting Orphan Drug Market Exclusivity.
    Socal MP; Parasrampuria S; Anderson GF
    Value Health; 2020 Nov; 23(11):1470-1476. PubMed ID: 33127018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Evergreened Reformulations on Medicaid Expenditures and Patient Access from 2008 to 2016.
    Dickson S
    J Manag Care Spec Pharm; 2019 Jul; 25(7):780-792. PubMed ID: 30799664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follow-on biologics: data exclusivity and the balance between innovation and competition.
    Grabowski H
    Nat Rev Drug Discov; 2008 Jun; 7(6):479-88. PubMed ID: 18469828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.